Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Exit

Passage Bio pushes proceeds to $248m
Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.
Boosted loses momentum
Electric skateboard producer Boosted, backed by Stanford-StartX Fund, has laid off employees after its business model succumbed amid the US-China tariff war.
Transphorm shapes reverse merger
The UC Santa Barbara-founded semiconductor technology producer has gone public through a reverse merger with penny stock company Peninsula Acquisition and received $21.5m from investors including Marelli.
Mellanox lays up Titan IC for acquisition
QUB-founded cybersecurity business Titan IC is set to become part of Mellanox Technologies, having previously raised funds in 2015.
Cambricon clambers for public listing
Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.
ABB to sweep up Cylon
ABB has agreed to purchase building control point supplier Cylon Controls, providing exits to UCD and energy utility ESB.
Passage Bio takes $216m IPO journey
University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.
Takeda to pay up to $330m for PvP
Takeda has bought UW spinout PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

Other News

OMass Therapeutics captures Excellerate
Nottingham-founded Excellerate Biosciences has been bought by Oxford's spinout OMass Therapeutics, which unveiled a series A extension last week.
McKinsey soaks up Orpheus
McKinsey has bought UVC Partners-backed Orpheus to implement a new service using the company's spending analytics technology.
Revolution hits public markets in $238m IPO
The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.
Beam Therapeutics brings IPO to $207m close
The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.
Beam Therapeutics shines in $180m IPO
Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.
ALD NanoSolutions forges ahead with $20m
CU Boulder spinout ALD NanoSolutions has merged with its peer Forge Nano, with new merged company securing $20m from a range of corporates.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login